SEC Form 4 · accession 0000908662-16-000379
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yat Sun Or
Officer — Chief Scientific Officer
Period of report
Jan 4, 2016
Accepted (ET)
Jan 5, 2016 · 6:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 4, 2016 | M | 50,723 | $2.9739 | A | 258,954 | D | |
| Common Stock | Jan 4, 2016 | M | 13,921 | $1.9826 | A | 272,875 | D | |
| Common Stock | Jan 4, 2016 | M | 13,921 | $1.5085 | A | 286,796 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.9739 | Jan 4, 2016 | M | 50,723 | D | — | Jul 12, 2017 | Common Stock | 50,723 | 0 | D |
| Stock Option (right to buy)F1 | $1.9826 | Jan 4, 2016 | M | 13,921 | D | — | Jul 11, 2018 | Common Stock | 13,921 | 0 | D |
| Stock Option (right to buy)F1 | $1.5085 | Jan 4, 2016 | M | 13,921 | D | — | Mar 5, 2019 | Common Stock | 13,921 | 0 | D |
Explanation of responses
- F1100% of the shares subject to the option are fully vested and exercisable.